[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-355603-105":59,"doc-detail-355603-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","data-mining-for-identification-of-targets-and-repurposed-drugs-to-eliminate-persistent-chronic-myeloid-leukaemia-stem-cells-targeting-rasraf-signalling","Data Mining for Identification of Targets and Repurposed Drugs to Eliminate Persistent Chronic Myeloid Leukaemia Stem Cells - Targeting RAS/RAF Signalling","","Persistent leukaemic stem cells (LSCs) in chronic myeloid leukaemia (CML) resist targeted tyrosine kinase inhibitors (TKIs), motivating discovery of alternative molecular vulnerabilities. The study identified active components of the RAS/RAF signalling pathway in persistent CML-LSCs using public datasets, aiming to propose a drug combination synergising with TKI therapy. Analyses combined single-cell expression resources, DESeq2 in R, dependency and inhibitor sensitivity from DepMap, and candidate discovery via DrugBank. PPP2CA showed strong dependency and consistently high expression; LB-100 emerged as a PP2A inhibitor candidate with broad cancer-cell effects. Limitations include public-dataset variation; further validation in patient-derived samples is required.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/data-mining-for-identification-of-targets-and-repurposed-drugs-to-eliminate-persistent-chronic-myeloid-leukaemia-stem-cells-targeting-rasraf-signalling/355603/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/data-mining-for-identification-of-targets-and-repurposed-drugs-to-eliminate-persistent-chronic-myeloid-leukaemia-stem-cells-targeting-rasraf-signalling/355603.png","ImageObject",300,407,{"name":92,"@type":93},"Fahsai","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is targeting leukaemic stem cells in CML important despite TKI therapy?","Question",{"text":112,"@type":113},"Persistent CML leukaemic stem cells (LSCs) are insensitive to targeted tyrosine kinase inhibitors (TKIs). Identifying alternative vulnerabilities may open new therapeutic opportunities.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which datasets and analytical tools were used to study RAS/RAF signalling in persistent CML-LSCs?",{"text":117,"@type":113},"EMBL-EBI Single Cell Expression Atlas and Stemformatics were used for pathway gene-expression analysis with DESeq2 in R Studio. Gene dependency and inhibitor sensitivity were evaluated using DepMap, and candidate inhibitors were identified with DrugBank.",{"name":119,"@type":110,"acceptedAnswer":120},"What key findings were reported for PPP2CA and LB-100?",{"text":121,"@type":113},"PPP2CA showed broad essentiality with negative Chronos scores, consistent high expression in CML, and strong gene dependency. LB-100 was identified as a PP2A inhibitor candidate and was reported to affect 548 cancer cell lines broadly.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},355603,1790387192,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},549768702563,"https://ap-avatar.wpscdn.com/avatar/8000c4aa63b76e948b?x-image-process=image/resize,m_fixed,w_180,h_180&k=1786536092046926083","Tech Science Press  \n[https://doi. org/10.32604/or.2026.074734](https://doi. org/10.32604/or.2026.074734)  \nARTICLE  \nData Mining for Identification of Targets and Repurposed Drugs to Eliminate Persistent Chronic Myeloid Leukaemia Stem Cells: Targeting RAS/RAF Signalling  \nI Made BayuAnggriawan1,2,3, * and Heather G. Jørgensen4, *  \n1 School of Medicine, Dentistry and Nursing, College of MVLS, University of Glasgow, Glasgow, UK 2 Ngoerah General Hospital, Ministry of Health, Denpasar, Indonesia  \n3 Lembaga Pengelola Dana Pendidikan (LPDP), Jakarta, Indonesia  \n4 School of Cancer Sciences, College of MVLS, University of Glasgow, Glasgow, UK  \n*Corresponding Authors: I Made Bayu Anggriawan. Email: [imadebayu13@gmail.com](imadebayu13@gmail.com); Heather G. Jørgensen. Email: [Heather.Jorgensen@glasgow.ac.uk](Heather.Jorgensen@glasgow.ac.uk)  \nReceived: 16 October 2025; Accepted: 04 February 2026; Published: 22 April 2026  \nABSTRACT: Background: Persistent leukaemic stem cells (LSCs) in chronic myeloid leukaemia (CML) are insensitive to targeted tyrosine kinase inhibitors (TKIs) . Identifying alternative molecular vulnerabilities may offer new therapeutic opportunities. This study aimed to identify active RAS/RAF signalling pathway components in persistent CML-LSCsusing publicly available datasets to propose a novel drug combination that could synergise with TKI therapy. Methods: EMBL-EBI Single Cell Expression Atlas and Stemformatics were used to analyse gene expression within the chosen signalling pathway using DESeq2 analysis in R Studio. Genes that showed statistically significant differences across three comparisons (CML vs. normal; post vs. pre TKI; post TKI vs. normal) were evaluated for gene dependency (Chronos scores), expression profiles, and inhibitor sensitivity using the DepMap platform, with a focus on CML cell lines. Candidate inhibitors were identified using DrugBank. Results: PPP2CA demonstrated broad essentiality with negative Chronos scores consistent with strong gene dependency. Its expression was consistently high, reinforcing its biological relevance in CML. LB-100 was found as a PP2A inhibitor under trial. Sensitivity analysis revealed LB-100 affected 548 cancer cell lines broadly. Conclusion: PPP2CA represents a promising therapeutic vulnerability in CML, supported by both strong dependency and consistent expression in myeloid models, while BRAF showed limited relevance outside mutation-driven cancers. Variation in experimental platforms, sample representation, and data integration across public datasets is a recognised study limitation. Nonetheless, LB-100 may provide a novel therapeutic avenue in CML, provided further preclinical functional and clinical validation is performed in patient-derived samples to confirm translational applicability of the findings.  \nKEYWORDS: Chronic myeloid leukaemia (CML); leukaemic stem cells (LSCs); tyrosine kinase inhibitors (TKIs); RAS/RAF signalling pathway; PPP2CA; and drug repurposing/combination therapy  \n1 Introduction  \nChronic myeloid leukaemia (CML) arises as a clonal myeloproliferative disorder caused by the Philadelphia chromosome, t(9;22), which forms the BCR::ABL1 fusion gene. This gene produces a persistently active tyrosine kinase that underlies disease development by transforming normal haematopoietic stem cells (HSCs) into leukaemia stem cells (LSCs) [1] . The continuous activation of this kinase plays a critical role in disease progression, traditionally described as progressing from the chronic phase (CP) to the accelerated  \nCopyright © 2026 The Authors. Published by Tech Science Press. This work is licensed under a Creative Commons Attribution 4.0 International License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.  \nphase (AP), and ultimately to blast crisis (BC), where leukaemic proliferation becomes uncontrolled [1–3] . However, the World Health Organization (WHO) has recen","cbCaighRSmqYQUtH","https://ap.wps.com/l/cbCaighRSmqYQUtH","pdf",6840286,25,"English","# Abstract\n# Introduction\n## Disease background and progression\n## Current therapies and limitations","[{\"question\":\"Why is targeting leukaemic stem cells in CML important despite TKI therapy?\",\"answer\":\"Persistent CML leukaemic stem cells (LSCs) are insensitive to targeted tyrosine kinase inhibitors (TKIs). Identifying alternative vulnerabilities may open new therapeutic opportunities.\"},{\"question\":\"Which datasets and analytical tools were used to study RAS/RAF signalling in persistent CML-LSCs?\",\"answer\":\"EMBL-EBI Single Cell Expression Atlas and Stemformatics were used for pathway gene-expression analysis with DESeq2 in R Studio. Gene dependency and inhibitor sensitivity were evaluated using DepMap, and candidate inhibitors were identified with DrugBank.\"},{\"question\":\"What key findings were reported for PPP2CA and LB-100?\",\"answer\":\"PPP2CA showed broad essentiality with negative Chronos scores, consistent high expression in CML, and strong gene dependency. LB-100 was identified as a PP2A inhibitor candidate and was reported to affect 548 cancer cell lines broadly.\"}]","Data Mining for Identification of Targets and Repurposed Drugs to Eliminate Persistent Chronic Myeloid Leukaemia Stem Cells - Targeting RAS/RAF Signalling | PDF",1790120100,63,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b062912f6c5bdaa6b287bbbc56b8b0fb.webp",983,1271,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dc7892fe58a5698016cb76b09012a52d.webp",982,1270,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4b09dffcb0ff0c02e76ff416815939d2.webp",981,1269,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ce8bc8716ddedb369bd7fa0ca57ed7d7.webp",980,1267]